¶ Person-time for unvaccinated persons included unvaccinated person-time before COVID-19 vaccination among COVID-19 vaccinees, and unvaccinated person-time of persons who did not receive a COVID-19 vaccine by May 31, 2021. Index dates were assigned to all persons on the basis of the distribution of vaccination dates among vaccinated persons. In this cohort study of VSD members aged ≥12 years, vaccination status through was determined. VSD, a collaborative project between CDC’s Immunization Safety Office and nine health care organizations, collects electronic health data, including information on vaccines, for specific studies. This finding reinforces the safety profile of currently approved COVID-19 vaccines in the United States. There is no increased risk for mortality among COVID-19 vaccine recipients. The aRR after receipt of the Janssen vaccine was 0.54 (95% CI = 0.49–0.59). After adjusting for demographic characteristics and VSD site, this study found that adjusted relative risk (aRR) of non–COVID-19 mortality for the Pfizer-BioNTech vaccine was 0.41 (95% confidence interval = 0.38–0.44) after dose 1 and 0.34 (95% CI = 0.33–0.36) after dose 2.

§ After standardizing mortality rates by age and sex, this study found that COVID-19 vaccine recipients had lower non–COVID-19 mortality than did unvaccinated persons. To assess mortality not associated with COVID-19 (non–COVID-19 mortality) after COVID-19 vaccination in a general population setting, a cohort study was conducted during December 2020–July 2021 among approximately 11 million persons enrolled in seven Vaccine Safety Datalink (VSD) sites. A cohort study of 19,625 nursing home residents found that those who received an mRNA vaccine (Pfizer-BioNTech or Moderna) had lower all-cause mortality than did unvaccinated residents ( 5), but no studies comparing mortality rates within the general population of vaccinated and unvaccinated persons have been conducted. However, daily vaccination rates have declined approximately 78% since Ap† vaccine safety concerns have contributed to vaccine hesitancy ( 4). By September 21, 2021, an estimated 182 million persons in the United States were fully vaccinated against COVID-19.* Clinical trials indicate that Pfizer-BioNTech (BNT162b2), Moderna (mRNA-1273), and Janssen (Johnson & Johnson Ad.26.COV2.S) vaccines are effective and generally well tolerated ( 1– 3).

Pfizer covid vaccine infographic